Iberdomide
- Generic Name
- Iberdomide
- Drug Type
- Small Molecule
- Chemical Formula
- C25H27N3O5
- CAS Number
- 1323403-33-3
- Unique Ingredient Identifier
- 8V66F27X44
- Background
Iberdomide (CC-220) has been used in trials studying the treatment of Systemic Lupus Erythematosus.
Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat Lymphoma
- Conditions
- Lymphoma, B-Cell
- Interventions
- First Posted Date
- 2021-05-12
- Last Posted Date
- 2025-03-24
- Lead Sponsor
- Celgene
- Target Recruit Count
- 174
- Registration Number
- NCT04884035
- Locations
- 🇬🇷
Local Institution - 703, Patras, Greece
🇨🇳Taichung Veterans General Hospital, Taichung City, Taiwan
🇺🇸Mayo Clinic - Arizona, Scottsdale, Arizona, United States
Study to Evaluate Tolerability of Iberdomide (CC-220) in Combination With Polatuzumab Vedotin Plus Rituximab or Tafasitamab or Rituximab Plus Chemotherapy in B-cell Lymphoma
- Conditions
- Lymphoma, B-Cell
- Interventions
- First Posted Date
- 2021-05-11
- Last Posted Date
- 2021-10-05
- Lead Sponsor
- Celgene
- Registration Number
- NCT04882163
- Locations
- 🇬🇧
Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸Avera Cancer Institute, Sioux Falls, South Dakota, United States
Safety and Efficacy of bb2121 (Ide-cel) Combinations in Multiple Myeloma
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2021-04-22
- Last Posted Date
- 2025-05-15
- Lead Sponsor
- Celgene
- Target Recruit Count
- 21
- Registration Number
- NCT04855136
- Locations
- 🇺🇸
Local Institution - 109, Hackensack, New Jersey, United States
🇺🇸Local Institution - 114, Chicago, Illinois, United States
🇺🇸Local Institution - 108, Boston, Massachusetts, United States
Iberdomide Alone or in Combination With Dexamethasone for the Treatment of Intermediate- or High-Risk Smoldering Multiple Myeloma
- Conditions
- Smoldering Plasma Cell Myeloma
- Interventions
- First Posted Date
- 2021-03-01
- Last Posted Date
- 2024-07-15
- Lead Sponsor
- Emory University
- Target Recruit Count
- 68
- Registration Number
- NCT04776395
- Locations
- 🇺🇸
Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States
Iberdomide (Cc220) Maintenance After Asct in Newly Diagnosed MM Patients
- First Posted Date
- 2020-09-25
- Last Posted Date
- 2025-02-25
- Lead Sponsor
- Stichting European Myeloma Network
- Target Recruit Count
- 160
- Registration Number
- NCT04564703
- Locations
- 🇬🇷
Alexandra General Hospital -Department of Clinical Therapeutics N.K. Univ. of Athens, Athens, Greece
🇫🇷CHU Hôtel-Dieu, 1, place Alexis Ricordeau, 44093 NANTES Cedex 1, FRANCE, Nantes, France
🇮🇹Ospedale Generale Regionale-Divisione di Ematologia e Centro Trapianto Midollo Osseo, Bolzano, Italy
A Dose Finding and Safety Study of CC-220, Alone and in Combination With an Anti-CD20 Monoclonal Antibody (mAb) in Subjects With Relapsed or Refractory Lymphomas
- First Posted Date
- 2020-07-09
- Last Posted Date
- 2025-04-29
- Lead Sponsor
- Celgene
- Target Recruit Count
- 62
- Registration Number
- NCT04464798
- Locations
- 🇫🇷
Local Institution - 205, Pessac, France
🇰🇷Local Institution - 501, Seoul, Korea, Republic of
🇺🇸Local Institution - 105, Lake Mary, Florida, United States
Iberdomide Combined With Low-dose Cyclophosphamide and Dexamethasone
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2020-05-18
- Last Posted Date
- 2025-03-28
- Lead Sponsor
- Amsterdam UMC, location VUmc
- Target Recruit Count
- 60
- Registration Number
- NCT04392037
- Locations
- 🇳🇱
Amsterdam UMC, location AMC, Amsterdam, Netherlands
🇳🇱Rijnstate, Arnhem, Netherlands
🇳🇱Albert Schweitzer Ziekenhuis, Dordrecht, Netherlands
Evaluate the Pharmacokinetics of CC-220 in Subjects With Mild, Moderate, or Severe Hepatic Impairment Compared With Healthy Subjects
- First Posted Date
- 2019-01-31
- Last Posted Date
- 2020-07-27
- Lead Sponsor
- Celgene
- Target Recruit Count
- 40
- Registration Number
- NCT03824678
- Locations
- 🇺🇸
Orlando Clinical Research Center OCRC, Orlando, Florida, United States
🇺🇸The Texas Liver Institute, San Antonio, Texas, United States
🇺🇸Clinical Pharmacology of Miami, LLC, Miami, Florida, United States
A Safety and Efficacy Trial of JCAR017 Combinations in Subjects With Relapsed/Refractory B-cell Malignancies
- Conditions
- Lymphoma, Non-HodgkinLymphoma, Large B-Cell, DiffuseLymphoma, Follicular
- Interventions
- First Posted Date
- 2017-10-16
- Last Posted Date
- 2024-04-04
- Lead Sponsor
- Celgene
- Target Recruit Count
- 62
- Registration Number
- NCT03310619
- Locations
- 🇺🇸
Local Institution - 015, Omaha, Nebraska, United States
🇺🇸Local Institution - 016, Philadelphia, Pennsylvania, United States
🇺🇸Local Institution - 011, Duarte, California, United States
Radiolabeled Study of CC-220 in Healthy Male Subjects
- First Posted Date
- 2017-09-27
- Last Posted Date
- 2017-10-25
- Lead Sponsor
- Celgene
- Target Recruit Count
- 6
- Registration Number
- NCT03294603
- Locations
- 🇺🇸
Covance Clinical Research Unit, Madison, Wisconsin, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.